The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT)
|ClinicalTrials.gov Identifier: NCT01331967|
Recruitment Status : Completed
First Posted : April 8, 2011
Last Update Posted : March 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Stable Angina Diabetic Unstable Angina||Drug: Pioglitazone||Phase 4|
People with diabetes mellitus are more prone to coronary heart disease, stroke, and peripheral vascular disease, and diabetes mellitus has been regarded as an independent risk factor for the progression of coronary artery disease. Several studies have been reported that diabetes increased the risk of cardiovascular mortality in both men and women. With the introduction of drug-eluting stents (DESs), the angiographic rates of restenosis at later months have reduced dramatically in several studies. However, even with DESs, diabetic patients showed increased rates of restenosis and late loss index compared with nondiabetic patients. Diabetes has been considered to be a predictor of poor prognosis after percutaneous coronary intervention with drug-eluting stents. Long-term clinical and angiographic outcomes after percutaneous coronary intervention (PCI) with drug-metal stents (DESs) have been demonstrated to be worse in diabetic patients compared with nondiabetic patients. In the era of DESs, no study has demonstrated the clinical and angiographic outcomes in diabetic patients after DES implantation by using optical coherence tomography (OCT).
Various microRNAs such as miRNA-21, -126, -143, -145 are involved in the restenosis and atherosclerosis progression (Figure 1). Changes in these miRNAs from baseline to 9 months after randomization have never been studied, and the effects of pioglitazone in correlation with the changes in various miRNAs could be utilized in clinical practices. Comparison of pioglitazone and placebo on 9 months follow-up neointima volume and neointima characteristics by optical coherence tomography (OCT) will be conducted.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||94 participants|
|Intervention Model:||Parallel Assignment|
|Study Start Date :||February 2011|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||August 2013|
|Experimental: Pioglitazone, Placebo||
Pioglitazone 15-30mg, once daily for 9 months
- 9 months follow-up neointima volume and neointima characteristics [ Time Frame: 9 months follow-up ]Comparison of pioglitazone and placebo on 9 months follow-up neointima volume and neointima characteristics by optical coherence tomography (OCT). Moreover, changes in miRNA-21.-126, -143, -145 from baseline to 9 months will be compared.
- major adverse cardiovascular events [ Time Frame: 9 months follow-up ]Comparison of pioglitazone and placebo on 9 months follow-up atheroma characteristics. Moreover, major adverse cardiovascular events such as non-fatal MI, death, stroke, and TLR will be compared.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01331967
|Korea, Republic of|
|Korea University Anam Hospital|
|Seoul, Korea, Republic of, 136705|